Glenmark Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Bonus
• Share holding
• Capital structures
• Ratio

Sep ' 23	Sep ' 22	Mar ' 22	Sep ' 21	Mar ' 20

Sales

4,377.80

4,120.14

3,818.60

4,322.98

3,424.02

Operating profit

955.85

816.25

672.07

1,016.15

615.06

Interest

120.12

92.23

123.78

112.26

123.15

Gross profit

931.30

1,387.27

944.01

1,122.80

837.69

EPS (Rs)

20.34

32.45

26.73

44.08

24.62

Other income

95.58

663.25

395.73

218.90

345.78

Stock adjustment

-17.01

-61.11

-15.81

-0.33

38.37

Raw material

1,603.79

1,547.09

1,332.67

1,660.37

1,165.02

Power and fuel

-

-

-

-

-

Employee expenses

717.47

683.22

579.89

613.31

506.52

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

1,117.71

1,134.69

1,249.78

1,033.48

1,099.06

Provisions made

-

-

-

-

-

Depreciation

98.60

91.20

82.57

77.13

73.05

Taxation

207.40

380.34

107.32

232.33

88.48

Net profit / loss

574.01

915.73

754.12

1,243.67

694.71

Extra ordinary item

-51.30

-

-

430.33

18.55

Prior year adjustments

-

-

-

-

-

Equity capital

28.22

28.22

28.22

28.22

28.22

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

21.83

19.81

17.60

23.51

17.96

GPM (%)

20.82

29.00

22.40

24.72

22.22

NPM (%)

12.83

19.14

17.89

27.38

18.43